Edition:
United States

PTC Therapeutics Inc (PTCT.OQ)

PTCT.OQ on NASDAQ Stock Exchange Global Select Market

25.52USD
23 Feb 2018
Change (% chg)

$-0.14 (-0.55%)
Prev Close
$25.66
Open
$25.74
Day's High
$25.79
Day's Low
$24.40
Volume
181,000
Avg. Vol
318,377
52-wk High
$28.70
52-wk Low
$8.14

Latest Key Developments (Source: Significant Developments)

PTC Therapeutics Receives Formal Dispute Resolution Request Decision
Tuesday, 20 Feb 2018 08:00am EST 

Feb 20 (Reuters) - PTC Therapeutics Inc ::PTC THERAPEUTICS RECEIVES FORMAL DISPUTE RESOLUTION REQUEST DECISION FROM THE FDA'S OFFICE OF NEW DRUGS.PTC THERAPEUTICS INC - OFFICE OF NEW DRUGS OF U.S. FDA DENIED PTC'S APPEAL OF COMPLETE RESPONSE LETTER IN RELATION TO NDA FOR ATALUREN.PTC THERAPEUTICS INC - OFFICE OF NEW DRUGS RECOMMENDED A POSSIBLE PATH FORWARD FOR ATALUREN NDA SUBMISSION BASED ON ACCELERATED APPROVAL PATHWAY.PTC THERAPEUTICS- LETTER FROM OFFICE OF NEW DRUGS ADDS CO'S STUDY 041 COULD SERVE AS CONFIRMATORY POST-APPROVAL TRIAL NEEDED FOR ACCELERATED APPROVAL.PTC THERAPEUTICS INC - PTC CURRENTLY INTENDS TO MAINTAIN PATIENTS IN U.S. CURRENTLY RECEIVING ATALUREN FOR NMDMD.  Full Article

PTC Therapeutics reports qtrly net loss per share basic and diluted of $0.82
Thursday, 2 Nov 2017 04:01pm EDT 

Nov 2 (Reuters) - Ptc Therapeutics Inc ::Qtrly total revenues $41.9 million versus $22.98 million.Qtrly net loss per share basic and diluted $0.82.Q3 earnings per share view $-0.68, revenue view $42.2 million -- Thomson Reuters I/B/E/S.Increasing 2017 revenue guidance to $160-$185M​.FY2017 revenue view $173.4 million -- Thomson Reuters I/B/E/S.  Full Article

PTC THERAPEUTICS ANNOUNCES DATA FROM PART 1 OF SUNFISH TRIAL
Tuesday, 3 Oct 2017 10:12am EDT 

Oct 3 (Reuters) - PTC Therapeutics Inc ::RG7916 INCREASED SMN PROTEIN PRODUCTION IN SUNFISH CLINICAL TRIAL IN PATIENTS WITH TYPE 2/3 SPINAL MUSCULAR ATROPHY.PTC THERAPEUTICS INC - RG7916 REMAINS WELL-TOLERATED IN PATIENTS AT ALL DOSES AND THERE HAVE BEEN NO DRUG-RELATED SAFETY FINDINGS LEADING TO WITHDRAWAL​.PTC THERAPEUTICS INC SAYS ANNOUNCED DATA FROM PART 1 OF SUNFISH TRIAL OF RG7916 IN TYPE 2/3 SPINAL MUSCULAR ATROPHY PATIENTS​.  Full Article

PTC Therapeutics files for potential mixed shelf; size not disclosed - SEC filing‍​
Thursday, 24 Aug 2017 06:07pm EDT 

Aug 24 (Reuters) - Ptc Therapeutics Inc :Files for potential mixed shelf; size not disclosed - SEC filing‍​.  Full Article

PTC Therapeutics qtrly loss per share $0.44
Tuesday, 8 Aug 2017 04:01pm EDT 

Aug 8 (Reuters) - Ptc Therapeutics Inc :Ptc therapeutics - qtrly total revenues $48 million versus $15.6 million; qtrly loss per share $0.44; sees fy translarna net sales $120 million - $140 million ‍​.Q2 earnings per share view $-1.28, revenue view $28.8 million -- Thomson Reuters I/B/E/S.Fy2017 revenue view $142.2 million -- Thomson Reuters I/B/E/S.  Full Article

Great Point Partners Llc reports 5.24 percent passive stake in PTC Therapeutics Inc
Friday, 16 Jun 2017 04:09pm EDT 

June 16 (Reuters) - Great Point Partners lLC::Great Point Partners LLC reports 5.24 percent passive stake in PTC Therapeutics Inc <<>> as of June 6, 2017 .  Full Article

PTC enters into credit and security agreement for senior secured term loan facility
Monday, 8 May 2017 07:44am EDT 

May 8 (Reuters) - Ptc Therapeutics Inc :Ptc therapeutics inc- on may 5, entered into a credit and security agreement for a senior secured term loan facility of $60.0 million - sec filing.Ptc therapeutics inc- final maturity date under credit agreement is may 1, 2021.Ptc therapeutics inc - on loan facility of $60.0 million, $40.0 million was drawn by company on may 5, 2017.Ptc therapeutics-$20.0 million under facility available upon co's demonstration, on/prior to dec 31, 2018, of net product revenue equaling/exceeding $120 million.  Full Article

PTC Therapeutics qtrly loss per share $0.85
Monday, 8 May 2017 07:30am EDT 

May 8 (Reuters) - PTC Therapeutics Inc : :Qtrly loss per share $0.85.Qtrly total revenues $26,5 million versus $18.9 million.PTC Therapeutics Inc - translarna net sales for 2017 are now anticipated to be between $115 and $130 million.PTC Therapeutics Inc -GAAP operating expenses for full year 2017 are anticipated to be between $250 to $260 million.  Full Article

Complete Pharma reports 16.2 pct passive stake in PTC Therapeutics
Thursday, 27 Apr 2017 06:08pm EDT 

April 27 (Reuters) - Ptc Therapeutics Inc :Complete Pharma Holdings II LLC reports 16.2 percent passive stake in PTC Therapeutics Inc as on April 20, 2017 - SEC filing.  Full Article

PTC Therapeutics reports departure of CFO
Monday, 10 Apr 2017 04:01pm EDT 

PTC Therapeutics Inc : PTC Therapeutics announces departure of chief financial officer, Shane Kovacs . PTC Therapeutics Inc says PTC has initiated a search process to appoint a new CFO .PTC Therapeutics - Shane is expected to remain with PTC through closing of PTC's pending acquisition of all rights to emflaza from Marathon Pharma.  Full Article

BRIEF-Boxer Capital Reports 6 Pct Passive Stake In ‍PTC Therapeutics​

* BOXER CAPITAL, LLC REPORTS 6 PERCENT PASSIVE STAKE IN ‍ PTC THERAPEUTICS, INC AS OF JANUARY 16, 2018 - SEC FILING​ Source text - http://bit.ly/2FkWr0i Further company coverage: